A novel pH-triggered in situ gel for sustained ophthalmic delivery of ketorolac tromethamine

Asian Journal of Pharmaceutical Sciences

Volumn 4, Issue 3, 2009, Pages 189-199

  Nanjwade, Basavaraj K ^a   Manjappa, A S ^a   Murthy, R S R ^b   Pol, Yuvaraj D ^a  

^a Karnatak Lingayat Education Society   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Carbopol 934; In situ gelation; Ketorolac tromethamine; Sustained ophthalmic delivery

Indexed keywords

BENZALKONIUM CHLORIDE; EDETATE DISODIUM; EXCIPIENT; KETOROLAC TROMETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; POLYACRYLIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EYE IRRITATION; GEL; GELATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH; RABBIT; SCANNING ELECTRON MICROSCOPY; VISCOSITY;

EID: 77953409341     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. N. Worakul, J. R. Robinson. Ocular pharmacokinetics/pharmacodynamics. Eur. J. Pharm. Biopharm., 1997, 44: 71-83.
2. K. Jarvinen, T. Jarvinen, A. Urtti. Ocular absorption following topical delivery. Adv. Drug Del. Rev., 1995, 6: 3-19.
3. T. J. Schoenwald. Ocular drug delivery: pharmacokinetic considerations. Cli. Pharmacokinet., 1990, 18: 255-269.
4. D. L. Middleton, S. S. Leung, J. R. Robinson. Bioadhesive Drug Delivery Systems. CRC Press, Boca Raton, 1990, pp. 179-202.
5. F. Thermes, A. Rozier, B. Plazonnet, et al. Bioadhesion: the effect of polyacrylic acid on the ocular bioavailability of timolol. Int. J. Pharm., 1992, 81: 59-65.
6. O. Felt, P. Furrer, J. M. Mayer, et al. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm., 1999, 180: 185-193.
7. O. Sechoy, G. Tissie, C. Sebastian, et al. A new long acting ophthalmic formulation of carteolol containing alginic acid. Int. J. Pharm., 2000, 207: 109-116.
8. R. Gurny, T. Boye, H. Ibrahim. Ocular therapy with nanoparticulate systems for controlled drug delivery. J. Control. Rel., 1985, 2: 353-361.
9. S. C. Miller, M. D. Donovan. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int. J. Pharm., 1982, 12: 147-152.
10. C. W. Spancake, A. K. Mitra, D. O. Kildsig. Kinetics of aspirin hydrolysis in aqueous solutions and gels of poloxamines (Tetronic 1508). Influence of microenvironment. Int. J. Pharm., 1991, 75: 231-239.
11. A. Rozier, C. Manuel, J. Groove, et al. Gelrite: A novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm., 1989, 57: 163-168.
12. Y. D. Sanzgiri, S. Maschi, V. Crescenzi, et al. Gellan-based systems for ophthalmic sustained delivery of methylprednisolone. J. Control. Rel., 1993, 26: 195-201.
13. C. A. Cooper, M. V. W. Bergamini, I. H. Leopold. Use of flurbiprofen to inhibit corneal neovascularization. Arch. Ophthalmol., 1980, 98: 1102-1105.
14. A. E. Searle, J. L. Pearce, D. E. Shaw. Topical use of indomethacin on the day of cataract surgery. Br. J. Pharmacol., 1990, 74: 19.
15. J. M. Mahoney, L. D. Waterbury. ( ± ) 5 benzoyl-1,2-dihydro-3H pyrollo [1,2a] pyrrole-1-carboxylic acid (RS 37619): a non irritating ophthalmic anti-inflammatory agent. Invest. Ophthalmol. Vis. Sci., 1983, 24: 151-159.
16. A. J. Flach, M. C. Kraff, D. R. Sanders, et al. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post surgical blood aqueous barrier. Arch. Ophthalmol., 1988, 106: 480-483.
17. J. Heier, J. K. Cheetham, R. Degryse. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized vehicle-controlled clinical trial. Am. J. Ophthalmol., 1999, 127: 253-259.
18. E. B. Fraser-Smith, T. R. Mathews. Effect of ketorolac on pseudomonas aeruginosa ocular infection in rabbits. J. Ocul. Pharmacol., 1988, 4: 101-109.
19. A. J. Flach, B. J. Dolan, A. R. Irvine. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudoaphakic cystoid macular edema. Am. J. Ophthalmol., 1987, 103: 479-486.
20. F. W. Price, M. O. Price, W. Zeh, et al. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, doublemasked, placebo controlled trial. J. Refract. Surg., 2002, 18: 140-144.
21. H. O. Ho, H. L. Su, T. Tsai, et al. The preparation and characterization of solid dispersions on pellets using a fluidized-bed system. Int. J. Pharm., 1996, 139: 223-229.
22. A. Gomez-Carracedo, C. A. Lorenzo, J. L. Gomez-Amoza, et al. Glass transitions and viscoelastic properties of Carbopol® and Noveon® compacts. Int. J. Pharm., 2004, 274: 233-243.
23. P. V. Devarajan, S. P. Gore, S. V. Chavan. HPTLC determination of ketorolac tromethamine. J. Pharm. Biomed. Anal., 2000, 22: 679-683.
24. H. Hagerstrom, M. Paulsson, K. Edsman. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur. J. Pharm. Sci., 2000, 9: 301-309.
25. T. J. Sanborn, P. B. Messersmith, A. E. Barron. In situ crosslinking of a biomimetic peptide-PEG hydrogel via thermally triggered activation of factor XIII. Biomaterials., 2002, 23: 2703-2710.
26. Z. Gao, P. Ding, L. Zhang, et al. Study of a Pingyangmycin delivery system: Zein/ Zein-SAIB in situ gels. Int. J. Pharm., 2007, 328: 57-64.
27. M. Malhotra, D. K. Mujumdar. In Vivo Ocular Availability of Ketorolac Following Ocular instillations of Aqueous, Oil and Ointment Formulations to Normal Corneas of Rabbits: A Technical Note. AAPS Pharm. Sci. Tech., 2005, 6: E523-E526.
28. L. L. Martinez, P. L. Lopez-de-Alba, R. G. Campos, et al. Simultaneous determination of methylxanthines in coffees and teas by UV-Vis spectrophotometry and partial least squares. Analytica. Chemica. Acta., 2003, 493: 83-94.
29. Nagaraj, K. Vipul, M. Rajshree. Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations. Anal. Sci., 2007, 23: 1-7.
30. J. H. Draize, G. Woodard, H. O. Calvery. Methods for the study of irritation and toxicity of substances. J. Pharmacol. Exp. Ther., 1944, 82: 377-390.
31. A. K. Dash, Z. Gong, D. W. Miller, et al. Development of a rectal nicotine delivery system for the treatment of ulcerative colitis. Int. J. Pharm., 1999, 190: 21-34.
32. L. A. Kanis, F. C. Viel, J. S. Crespo, et al. Study of poly(oxyethylene oxide)/carbopol blends through thermal analysis and infrared spectroscopy. Polymer., 2000, 41: 3303-3309.
33. J-K. Park, D-W. Kim, C-H. Kim, et al. Effect of drying conditions in the glass transition of poly(acrylic acid). Polym. Eng. Sci., 1991, 31: 867-872.
34. R. D. Schoenwald, R. L. Ward, L. M. DeSantis, et al. Influence of high-viscosity vehicles on miotic effect of pilocarpine. J. Pharm. Sci., 1978, 67(9): 1280-1283.
35. M. T. Kumar, D. Bharathi, J. Balasubramaniam, et al. pH-Induced In Situ Gelling Systems of Indomethacin for Sustained Ocular Delivery. Ind. J. Pharm. Sci., 2005, 67: 327-333.
36. B. Srividya, R. M. Cardoza, P. D. Amin. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Rel., 2001, 73: 205-211.
37. P. M. Hughes, A. K. Mitra. Ophthalmic Drug Delivery Systems. Marcel Dekker, New York, 1993, pp. 1.
38. R. C. Fu, D. M. Lidgate. In vitro rabbit corneal permeability study of ketorolac tromethamine. Drug Dev. Ind. Pharm., 1986, 12: 2403-2430.
39. G. M. Grass, R. W. Wood, J. R. Robinson. Effects of calcium chelating agents on corneal permeability. Invest. Ophthalmol. Vis. Sci., 1985, 26: 110.
40. H. E. Kennah, S. Hignet, P. E. Laux, et al. An objective procedure for quantitating eye irritation based upon changes of corneal thickness. Fundam. Appl. Toxicol., 1989, 12: 258-268.